Host: Jacob Sands, MD

Guest: Benjamin Levy, MD

What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.

Host: Jacob Sands, MD

Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter season.

Host: Jacob Sands, MD

Guest: Taofeek K. Owonikoko, MD, PhD, MSCR

After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medical Oncology at Emory University School of Medicine, joins Dr. Jacob Sands to talk about long-awaited developments in small cell lung cancer.

Host: Linda Bernstein, Pharm.D.

The U.S. Food and Drug Administration issued an emergency use authorization, or EUA, for the Moderna COVID-19 vaccine. The second vaccination to achieve EUA designation, the Moderna vaccine will be distributed throughout the US for patients 18 years and older. In this episode of The Drug Report, Dr. Linda Bernstein discusses this newly-approved vaccine and how it compares to others.

Published December 29, 2020

Host: Linda Bernstein, Pharm.D.

The first vaccine to receive Emergency Use Authorization from the US Food and Drug Administration, this authorization allows the Pfizer-BioNTech COVID-19 vaccine to be distributed throughout the US. But what do we know about this vaccine? In this episode of The Drug Report, Dr. Linda Bernstein discusses the Pfizer-BioNTech COVID-19 vaccine.

Published December 18, 2020

Host: Linda Bernstein, Pharm.D.

To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug.

Published December 2, 2020

Host: Linda Bernstein, Pharm.D.

With the spread of the COVID-19 pandemic, fewer children have received a measles vaccination, and progress towards eliminating this disease has halted. How can pharmacists encourage more pediatric measles vaccinations? In this episode of The Drug Report, Dr. Linda Bernstein takes a look at the vast number of children globally who’ve yet to receive this vaccine.

Published November 30, 2020

Host: Linda Bernstein, Pharm.D.

Pfizer and BioNTech recently announced that their mRNA vaccine for the COVID-19 virus was 90 percent effective, and the companies plan to apply for Emergency Use Authorization. This episode of The Drug Report dives into this vaccine’s Phase 3 clinical trial and explores developments made by other companies in the search for a COVID-19 vaccine.

Published November 30, 2020

Host: Linda Bernstein, Pharm.D.

This episode of The Drug Report takes a look at a COVID-19 cocktail comprised of the coadministration of casirivimab and imdevimab, which has proven to decrease hospitalization and emergency room visits.

Published November 30, 2020

Host: Linda Bernstein, Pharm.D.

The U.S. Food and Drug Administration has granted Eli Lilly and Company’s trial vaccine for COVID-19 an Emergency Use Authorization, or EUA. On this episode of The Drug Report, learn more about this monoclonal antibody and how the company plans on distributing it.

Published November 30, 2020